Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Undervalued Acute Leukopenia Induced By Radiotherapy In Cervical Cancer

Author(s): Xiaoxian Ye, Jianliang Zhou, Shenchao Guo, Pengrong Lou, Ruishuang Ma* and Jianxin Guo*

Volume 16, Issue 1, 2023

Published on: 17 October, 2022

Page: [50 - 56] Pages: 7

DOI: 10.2174/1874471015666221010141250

Price: $65

Abstract

Background: Myelosuppression is common and threatening during tumor treatment. However, the effect of radiation on bone marrow activity, especially leukocyte count, has been underestimated in cervical cancer. The aim of this study was to evaluate the severity of radiotherapy- induced acute leukopenia and its relationship with intestinal toxicity.

Methods: The clinical data of 59 patients who underwent conventional radiation alone for cervical cancer were retrospectively analyzed. The patients had normal leukocyte count on admission, and the blood cell count, gross tumor volume (GTV) dose, and intestinal toxicity were evaluated.

Results: During radiotherapy (RT), 47 patients (79.7%) developed into leukopenia, with 38.3% mild and 61.7% moderate. The mean time for leukopenia was 9 days. Compared with leukopenianegative patients, leukopenia-positive ones had lower baseline leukocyte count, while neutrophil/ lymphocyte (NLR) and monocyte/lymphocyte (MLR) showed no significance. Logistic regression analysis indicated that excluding the factors for age, body mass index (BMI), TNM stage, surgery and GTV dose, baseline leukocyte count was an important independent predictor of leukopenia (OR=0.383). During RT, a significant reduction was found in leukocyte, neutrophil and lymphocyte count at week 2 while monocyte count after 2 weeks. Furthermore, NLR and MLR showed a significant and sustained upward trend. About 54.2% of patients had gastrointestinal symptoms. However, no significant relevance was noted between leukocyte count as well as NLR/MLR and intestinal toxicity, indicating leukopenia may not be the main factor causing and aggravating gastrointestinal reaction in cervical cancer.

Conclusion: Our results suggest the underrated high prevalence and severity of leukopenia in cervical cancer patients receiving RT, and those with low baseline leukocyte count are more likely for leukopenia, for whom early prevention of infection may be needed during RT.

« Previous Next »
[1]
Cohen, P.A.; Jhingran, A.; Oaknin, A.; Denny, L. Cervical cancer. Lancet, 2019, 393(10167), 169-182.
[http://dx.doi.org/10.1016/S0140-6736(18)32470-X] [PMID: 30638582]
[2]
Koh, W.J.; Abu, R.N.R.; Bean, S.; Bradley, K.; Campos, S.M.; Cho, K.R.; Chon, H.S.; Chu, C.; Clark, R.; Cohn, D.; Crispens, M.A.; Damast, S.; Dorigo, O.; Eifel, P.J.; Fisher, C.M.; Frederick, P.; Gaffney, D.K.; Han, E.; Huh, W.K.; Lurain, J.R., III; Mariani, A.; Mutch, D.; Nagel, C.; Nekhlyudov, L.; Fader, A.N.; Remmenga, S.W.; Reynolds, R.K.; Tillmanns, T.; Ueda, S.; Wyse, E.; Yashar, C.M.; McMillian, N.R.; Scavone, J.L. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2019, 17(1), 64-84.
[http://dx.doi.org/10.6004/jnccn.2019.0001] [PMID: 30659131]
[3]
Gupta, S.; Maheshwari, A.; Parab, P.; Mahantshetty, U.; Hawaldar, R.; Sastri, C.S.; Kerkar, R.; Engineer, R.; Tongaonkar, H.; Ghosh, J.; Gulia, S.; Kumar, N.; Shylasree, T.S.; Gawade, R.; Kembhavi, Y.; Gaikar, M.; Menon, S.; Thakur, M.; Shrivastava, S.; Badwe, R. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: A randomized controlled trial. J. Clin. Oncol., 2018, 36(16), 1548-1555.
[http://dx.doi.org/10.1200/JCO.2017.75.9985] [PMID: 29432076]
[4]
Naga CH, P.; Gurram, L.; Chopra, S.; Mahantshetty, U. The management of locally advanced cervical cancer. Curr. Opin. Oncol., 2018, 30(5), 323-329.
[http://dx.doi.org/10.1097/CCO.0000000000000471] [PMID: 29994902]
[5]
Kim, H.J.; Chang, J.S.; Koom, W.S.; Lee, K.C.; Kim, G.E.; Kim, Y.B. Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer. Gynecol. Oncol., 2018, 151(2), 208-214.
[http://dx.doi.org/10.1016/j.ygyno.2018.08.029] [PMID: 30195468]
[6]
Matsuo, K.; Nusbaum, D.J.; Machida, H.; Huang, Y.; Khetan, V.; Matsuzaki, S.; Klar, M.; Grubbs, B.H.; Roman, L.D.; Wright, J.D. Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: Concurrent chemo-radiotherapy versus radiotherapy alone. Am. J. Obstet. Gynecol., 2020, 222(5), 484.e1-484.e15.
[http://dx.doi.org/10.1016/j.ajog.2019.10.010] [PMID: 31678092]
[7]
Klopp, A.H.; Yeung, A.R.; Deshmukh, S.; Gil, K.M.; Wenzel, L.; Westin, S.N.; Gifford, K.; Gaffney, D.K.; Small, W., Jr; Thompson, S.; Doncals, D.E.; Cantuaria, G.H.C.; Yaremko, B.P.; Chang, A.; Kundapur, V.; Mohan, D.S.; Haas, M.L.; Kim, Y.B.; Ferguson, C.L.; Pugh, S.L.; Kachnic, L.A.; Bruner, D.W. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology–RTOG 1203. J. Clin. Oncol., 2018, 36(24), 2538-2544.
[http://dx.doi.org/10.1200/JCO.2017.77.4273] [PMID: 29989857]
[8]
Weitzner, O.; Yagur, Y.; Kadan, Y.; Beiner, M.E.; Fishman, A.; Ben Ezry, E.; Amitai Komem, D.; Helpman, L. Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy. Oncologist, 2019, 24(12), e1471-e1475.
[http://dx.doi.org/10.1634/theoncologist.2019-0272] [PMID: 31346131]
[9]
Narayan, V.; Vaughn, D. Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. Expert Opin. Drug Metab. Toxicol., 2015, 11(5), 731-742.
[http://dx.doi.org/10.1517/17425255.2015.1005600] [PMID: 25604887]
[10]
Testart, P.D.; Girard, P.; You, B.; Freyer, G.; Pobel, C.; Tranchand, B. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit. Rev. Oncol. Hematol., 2007, 63(1), 1-11.
[http://dx.doi.org/10.1016/j.critrevonc.2007.01.005] [PMID: 17418588]
[11]
Hale, M.F. Radiation enteritis. Curr. Opin. Gastroenterol., 2020, 36(3), 208-214.
[http://dx.doi.org/10.1097/MOG.0000000000000632] [PMID: 32141897]
[12]
U.S. Department of Health and Human Services. Common terminal criteria for adverse events (CTCAE, version 5.0) National Institutions of Health, National Cancer Institution., 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
[13]
Zachariah, B.; Jacob, S.S.; Gwede, C.; Cantor, A.; Patil, J.; Casey, L.; Zachariah, A.B. Effect of fractionated regional external beam radiotherapy on peripheral blood cell count. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50(2), 465-472.
[http://dx.doi.org/10.1016/S0360-3016(00)01587-X] [PMID: 11380235]
[14]
Blank, K.R.; Cascardi, M.A.; Kao, G.D. The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1999, 44(2), 317-321.
[http://dx.doi.org/10.1016/S0360-3016(99)00018-8] [PMID: 10760425]
[15]
Yang, F.E.; Vaida, F.; Ignacio, L.; Houghton, A.; Nautiyal, J.; Halpern, H.; Sutton, H.; Vijayakumar, S. Analysis of weekly complete blood counts in patients receiving standard fractionated partial body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 1995, 33(3), 607-617.
[http://dx.doi.org/10.1016/0360-3016(95)00255-W] [PMID: 7558950]
[16]
Hellman, S.; Fink, M. Granulocytie reserve following radiation therapy as studied by tbe response to a bacterial endotoxin. Blood, 1965, 25(3), 310-324.
[http://dx.doi.org/10.1182/blood.V25.3.310.310] [PMID: 14263206]
[17]
Dovšak, T.; Ihan, A.; Didanovič, V.; Kansky, A.; Verdenik, M.; Hren, N.I. Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer. BMC Cancer, 2018, 18(1), 235.
[http://dx.doi.org/10.1186/s12885-018-4136-9] [PMID: 29490633]
[18]
Trask, C.W.L.; Llewellyn, I.; Souhami, R.L. The effect of radiotherapy on blood mononuclear cell numbers and phagocyte migration. Clin. Radiol., 1980, 31(6), 733-738.
[http://dx.doi.org/10.1016/S0009-9260(80)80032-8] [PMID: 6971205]
[19]
Lu, L.; Li, W.; Chen, L.; Su, Q.; Wang, Y.; Guo, Z.; Lu, Y.; Liu, B.; Qin, S. Radiation-induced intestinal damage: Latest molecular and clinical developments. Future Oncol., 2019, 15(35), 4105-4118.
[http://dx.doi.org/10.2217/fon-2019-0416] [PMID: 31746639]
[20]
Pinkawa, M.; Ribbing, C.; Djukic, V.; Klotz, J.; Holy, R.; Eble, M.J. Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity. Strahlenther. Onkol., 2015, 191(10), 771-777.
[http://dx.doi.org/10.1007/s00066-015-0841-3] [PMID: 26009493]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy